{"id":704277,"date":"2024-06-26T17:12:02","date_gmt":"2024-06-26T17:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=704277"},"modified":"2024-06-26T17:12:02","modified_gmt":"2024-06-26T17:12:02","slug":"pd1-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pd1-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight_704277.html","title":{"rendered":"PD-1 Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1719406288.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"PD-1 Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1719406288.jpeg\" alt=\"PD-1 Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;&ldquo;<strong>PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2024<\/strong>&rdquo;&nbsp;report provides comprehensive insights about&nbsp;30+ companies and 30+ pipeline drugs&nbsp;in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the PD-1 Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1 Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Explore our latest breakthroughs in PD-1 Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>June 2024:- Merck Sharp &amp; Dohme LLC- A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer.<\/li>\n<li>June 2024:- AstraZeneca- An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1\/PD-L1 Containing Therapy (HUDSON). This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1\/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.<\/li>\n<li>DelveInsight&rsquo;s PD-1 Non-Small Cell Lung Cancer pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment.<\/li>\n<li>The leading PD-1 Non-Small Cell Lung Cancer Companies such as Novartis Pharmaceuticals, Merck Sharp &amp; Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo, Inc., Arcus Biosciences, Inc., IO Biotech, and Cellular Biomedicine Group, Inc., and others.<\/li>\n<li>Promising PD-1 Non-Small Cell Lung Cancer Therapies such as Durvalumab, AZD9150, AZD6738, REGN2810, Ipilimumab, Cemiplimab, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay informed about the cutting-edge advancements in PD-1 Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Tislelizumab (BGB-A317) &#8211; BeiGene<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Tislelizumab (BGB-A317) is a humanized IgG4 anti&ndash;PD-1 monoclonal antibody specifically designed to minimize binding to Fc&gamma;R on macrophages. In pre-clinical studies, binding to Fc&gamma;R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene&rsquo;s immuno-oncology biologics program and is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. stigated in the Phase III stage of development for the treatment of PD-1 Non-Small Cell Lung Cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Canakinumab: Novartis Pharmarmaceutical<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Canakinumab (ACZ885, Ilaris) is a human anti-IL-1&beta; monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of 1&beta; signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. Currently the driug is in phase III stage of development for the treatment of Non-Small Cell Lung Cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>PLB-1004: Avistone Biotechnology<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Avistone Biotechnology is developing PLB-1004, an oral EGFR inhibitor being studied in patients with non-small cell lung cancer. In December 2021, Avistone Pharmaceuticals, a clinical-stage biotechnology company focused on precision oncology therapeutics, announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Bain Capital and Primavera Capital. The investment will support the combination of Avistone with Pearl Biotechnology Co. Ltd. to create a fully-integrated targeted oncology platform that will address unmet patient needs globally. Based in Beijing, China, Avistone has been committed to the development of precision oncology therapeutics for nearly a decade and has a broad oncology pipeline focused on treatments for lung cancer. The Company&rsquo;s most advanced asset is a c-Met inhibitor in late-stage clinical development for genetically-defined populations of non-small cell lung cancer (NSCLC) and glioblastoma (GBM).<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about PD-1 Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking PD-1 Non-Small Cell Lung Cancer Research and development projects @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Oral<\/li>\n<li>Intramuscular<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal antibody<\/li>\n<li>Small molecule<\/li>\n<li>Peptide<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover the latest advancements in PD-1 Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we&#8217;re transforming the future of Oncology @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Companies- Novartis Pharmaceuticals, Merck Sharp &amp; Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo, Inc., Arcus Biosciences, Inc., IO Biotech, and Cellular Biomedicine Group, Inc., and others.<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Therapies- Durvalumab, AZD9150, AZD6738, REGN2810, Ipilimumab, Cemiplimab, and others.<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>For a detailed overview of our latest research findings and future plans, read the full details of PD-1 Non-Small Cell Lung Cancer Pipeline on our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Canakinumab: Novartis<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>MK-5890: Merck Sharp &amp; Dohme<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>BBP-398: Navire Pharma Inc.<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Key Products<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Unmet Needs<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Market Drivers and Barriers<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer- Future Perspectives and Conclusion<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Analyst Views<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pd1-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pd1-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s,&nbsp;&ldquo;PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2024&rdquo;&nbsp;report provides comprehensive insights about&nbsp;30+ companies and 30+ pipeline drugs&nbsp;in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the PD-1 Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pd1-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight_704277.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-704277","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/704277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=704277"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/704277\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=704277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=704277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=704277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}